PFM Health Sciences’s Belite Bio BLTE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.35M Buy
55,078
+20,275
+58% +$3.29M 0.93% 43
2026
Q2
$5.36M Sell
34,803
-24,629
-41% -$3.77M 0.46% 68
2026
Q1
$9.48M Buy
59,432
+39,609
+200% +$6.66M 0.86% 38
2025
Q4
$3.17M Buy
+19,823
New +$2.35M 0.32% 64

Other funds holding BLTE

PFM Health Sciences's BLTE Position: Q3 2026 in Review

PFM Health Sciences increased its Belite Bio (BLTE) stake by 58% in Q3 2026, buying an estimated $3.29M and bringing the position to 55,078 shares worth $9.35M. The position accounts for 0.93% of the portfolio, ranked #43.

PFM Health Sciences first reported a position in BLTE in Q4 2025 and has held it in 4 quarters since. The position peaked at $9.48M in Q1 2026. 96 funds tracked by Wall St. Rank hold BLTE as of Q3 2026.

  • PFM Health Sciences held 55,078 shares of Belite Bio worth $9.35M as of Q3 2026.
  • PFM Health Sciences bought 20,275 Belite Bio shares in Q3 2026, an estimated $3.29M.
  • Belite Bio made up 0.93% of PFM Health Sciences's portfolio in Q3 2026, its #43 holding.
  • PFM Health Sciences first reported a position in Belite Bio in Q4 2025 and has held it in 4 quarters since.
  • PFM Health Sciences's Belite Bio position peaked at $9.48M in Q1 2026.
  • 96 funds tracked by Wall St. Rank held Belite Bio as of Q3 2026.

Based on PFM Health Sciences's 13F filing for Q3 2026, filed 16 Nov 2026.